English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chamaecostus cuspidatus  (Nees &amp; Mart.) C.D.Specht &amp; D.W.Stev and  Cheilocostus speciosus  (J.Koenig) C.D.Specht contain bioactive compounds that possess many pharmacological activities including antidiabetic and hypolipidemic. These plants are used to treat diabetes by herbal healers. Considering the traditional use of  C. cuspidatus  and  C. speciosus , the present study is designed to perform qualitative and quantitative analysis as well as  in-vitro  anti-adipogenesis against 3T3-L1 cells to ensure efficacy. A total of thirty-eight compounds were identified using HPLC-QTOF-MS/MS. Quantification of ten bioactive compounds among identified compounds was performed by UPLC-QqQ LIT -MS/MS. The quantification method was validated according to ICH guidelines (International conference on harmonization guidelines). Quantification of bioactive compounds of different organs of  C. cuspidatus  and  C. speciosus  showed remarkable differences in the content. Microscopic and ORO absorbance confirmed the antiadipogenic potential of leaves (L-02), roots (R-02) of  C. cuspidatus  and leaves of  C. speciosus  (L-01) in 3T3-L1 cells.

natural product research

Identification and quantification of phytochemicals of  Chamaecostus cuspidatus  (Nees &amp; Mart.) C.D.Specht &amp; D.W.Stev and  Cheilocostus speciosus  (J. Koenig) C.D.Specht by LC-MS techniques and their  in - vitro  anti-adipogenic screening